CNBX Pharmaceuticals Reports Increased Net Loss and Declining Cash Reserves

CNBX Pharmaceuticals Inc. reported its financial results for the three months ending November 30, 2025, revealing a net loss of $113,719, a significant increase from the $34,352 loss recorded during the same period in 2024. The company did not generate any revenue during this quarter, maintaining a consistent trend from the previous year. Operating expenses rose to $64,002, up from $36,837 in the prior year, primarily due to increased general and administrative costs, including a notable rise in salary expenses.

The company's financial position showed a decrease in cash and cash equivalents, which fell to $7,703 from $17,339 a year earlier. Total current assets also declined to $11,162 compared to $18,437 as of August 31, 2025. Current liabilities increased slightly to $2,584,133 from $2,514,730, with a notable portion attributed to a convertible loan and short-term loans. The accumulated deficit grew to $25,382,095, reflecting the ongoing challenges in achieving profitability.

In terms of operational developments, CNBX Pharmaceuticals is focused on advancing its drug candidate RCC-33, aimed at treating colorectal cancer. The company plans to initiate Phase I/II clinical trials in 2025, which is a critical step in its strategy to address significant unmet medical needs in oncology. The company has also been active in restructuring its capital, having issued 199,234,460 shares in connection with the conversion of loans during the reporting period.

Looking ahead, CNBX Pharmaceuticals faces substantial challenges regarding its liquidity and ability to fund ongoing operations. The company anticipates incurring at least $150,000 in expenses over the next twelve months, primarily for general overhead and clinical study costs. Management has indicated that raising additional capital will be essential for sustaining operations, but there are no current arrangements in place to secure such funding. The company's ability to continue as a going concern remains uncertain, as highlighted by its independent auditors, who expressed concerns regarding the company's financial viability.

Overall, CNBX Pharmaceuticals is navigating a complex landscape as it seeks to develop its oncology therapies while managing financial constraints. The company's future will depend on its ability to secure funding and successfully advance its clinical programs, which are critical for its long-term growth and sustainability.